This suggests a potential of checkpoint inhibitors (CPI) in the treatment of PCNSL and suggests TIGIT, TIM-3, PD-1, CTLA-4, and LAG-3 as promising targets. The gene discussed is PDCD1; the disease is primary central nervous system lymphoma.